The FDA approved zopapogene imadenovec, the first therapy for recurrent respiratory papillomatosis, providing an option beyond repeated surgeries to manage the rare condition.

While the findings suggest that switching to onasemnogene abeparvovec after non–gene therapy treatments could be beneficial to patients with spinal muscular atrophy, it is not clear which patients may benefit the most from switching therapies. | Image credit: Rochu_2008 - stock.adobe.com

Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA

By Rose McNulty

August 15th 2025

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

By Rose McNulty

August 13th 2025

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).

The Impact of Health Benefit Design on Patients With Infertility

By Richard A. Brook, MS, MBA
Sanghyuk Seo, PharmD, MS

Ian A. Beren, BS
Tanyatorn Ghanjanasak, DO
Nathan L. Kleinman, PhD
Eric M. Rosenberg, MA
Emily S. Jungheim, MD

August 5th 2025

This retrospective analysis explored the impact of infertility health benefit design on the use of infertility medications and procedures and pregnancy outcomes.

...

39 40 41 42 43

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions